BioSpace News Archive

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today reported fourth quarter and full year 2020 financial results and provided a business update.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020.

Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb’s (NYSE: BMY) investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121), i

Doppler radar improves lives by peeking inside air masses to predict the weather. A Purdue University team is using similar technology to look inside living cells, introducing a method to detect pathogens and treat infections in ways that scientists never have before.

Birmingham-based Linear Diagnostics Ltd has secured £800,000 from the Midlands Engine Investment Fund (MEIF) and other investors in the company’s second round of funding, which will enable the company to commence the development of the hardware platform for its tests.

Real Time Medical Systems (Real Time), the leading interventional analytics solution in healthcare, joins the THA Center for Innovative Solutions (TCIS) as its newest Strategic Partner.

Elekta announced that several cancer centers are the early adopters of the company’s first release in the MOSAIQ® 3* series.

Solano Hematology Oncology and Deep Lens today announced a strategic collaboration designed to more effectively identify, screen and match patients to precision-based clinical oncology trials using VIPER™, Deep Lens’ artificial intelligence-based screening and enrollment platform

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer’s disease.